QCG
TXMD icon

Quadrant Capital Group’s TherapeuticsMD TXMD Stock Holding History

Quadrant Capital Group’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-12
Closed -$6K – 1992
2015
Q4 		$6K Buy
+12
New +$4.43K ﹤0.01% 1018

Other funds holding TXMD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Quadrant Capital Group's TXMD Position: Q1 2016 in Review

Quadrant Capital Group sold out of TherapeuticsMD (TXMD) in Q1 2016, closing a stake of 12 shares — an estimated $6K sold.

Quadrant Capital Group first reported a position in TXMD in Q4 2015 and held it in 1 quarter. The position peaked at $6K in Q4 2015. 128 funds tracked by Wall St. Rank hold TXMD as of Q1 2016.

  • Quadrant Capital Group reported no remaining TherapeuticsMD position as of Q1 2016 after selling out during the quarter.
  • Quadrant Capital Group sold 12 TherapeuticsMD shares in Q1 2016, an estimated $6K.
  • Quadrant Capital Group first reported a position in TherapeuticsMD in Q4 2015 and held it in 1 quarter.
  • Quadrant Capital Group's TherapeuticsMD position peaked at $6K in Q4 2015.
  • 128 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2016.

Based on Quadrant Capital Group's 13F filing for Q1 2016, filed 27 Apr 2016.